AlzeCure Pharma AB appointed Martin Jönsson as the company’s new CEO.
A specially designed clinical study that was the first disease prevention trial to study Alzheimer’s disease drugs with different mechanisms of action from two different pharmaceutical companies failed to hit the primary endpoint.
The best-known genetic marker for Alzheimer’s disease is ApoE4 – a form of apolipoprotein E – which is a protein involved in repairing neurons injured by aging, stroke or other reasons.
Investigators at the Case Western Reserve University School of Medicine identified a previously unknown gene and the resultant protein that may potentially slow the progress of Alzheimer’s disease.
Carlsbad, California-based Ionis Pharmaceuticals licensed the company’s IONIS-MAPTRX antisense therapy to leading biotech firm Biogen Inc.
After multiple failures to develop therapeutics for Alzheimer’s disease, Biogen’s Michael D. Ehlers resigned from his role as head of research and development.
Days after halting Biogen’s BACE inhibitor program for Alzheimer’s disease, the Cambridge-based company stopped a clinical trial in idiopathic pulmonary fibrosis due to safety reasons.
Researchers at Arizona State University are experimenting with a compound that might prevent Alzheimer’s and other neurodegenerative diseases, such as Parkinson’s disease, and potentially Down syndrome.
Researchers at Rutgers University-New Brunswick recently published research about a nanotechnology platform that helps identify what happens to specific stem cells.
Researchers with Massachusetts General Hospital have identified some crosstalk communication between TREM2 and CD33, two genes that play a role in inflammation and Alzheimer’s disease.
